Key Details
Price
$0.02Annual ROE
-1545.63%Beta
-2.86Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Jan 11, 2024Recent annual earnings:
Mar 21, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
28 Aug '23 Raymond James
Outperform17 May '23 Raymond James
Outperform17 May '23 Ladenburg Thalmann
Buy17 May '23 Goldman Sachs
Neutral10 Apr '23 Raymond James
Outperform07 Apr '23 Raymond James
Outperform22 Mar '23 Raymond James
Outperform22 Mar '23 Goldman Sachs
Neutral11 Nov '22 Raymond James
Outperform23 Aug '22 Ladenburg Thalmann
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
LumiraDx Limited doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Roche to buy part of LumiraDx diagnostics platform for $295 million
LMDX
Reuters29 December 2023
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.
Why Is LumiraDx (LMDX) Stock Down 35% Today?
LMDX
InvestorPlace24 October 2023
LumiraDx (NASDAQ: LMDX ) stock is falling on Tuesday as the point-of-care diagnostics company's shares retreat from a rally on Monday. Investors will note that LMDX stock underwent a 217% rally on Monday.
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
LMDX
Zacks Investment Research27 September 2023
LumiraDx Limited (LMDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
What Makes LumiraDx Limited (LMDX) a New Buy Stock
LMDX
Zacks Investment Research21 September 2023
LumiraDx Limited (LMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is LumiraDx (LMDX) Stock Up 30% Today?
LMDX
InvestorPlace21 June 2023
LumiraDx (NASDAQ: LMDX ) stock is heading higher on Wednesday morning after the company received approval for its Covid and RSV tests. The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) gave its approval to the company's test through its Coronavirus Test Device Approvals (CTDA) process.
FAQ
- What is the primary business of LumiraDx Limited?
- What is the ticker symbol for LumiraDx Limited?
- Does LumiraDx Limited pay dividends?
- What sector is LumiraDx Limited in?
- What industry is LumiraDx Limited in?
- What country is LumiraDx Limited based in?
- When did LumiraDx Limited go public?
- Is LumiraDx Limited in the S&P 500?
- Is LumiraDx Limited in the NASDAQ 100?
- Is LumiraDx Limited in the Dow Jones?
- When was LumiraDx Limited's last earnings report?
- When does LumiraDx Limited report earnings?
- Should I buy LumiraDx Limited stock now?
What is the primary business of LumiraDx Limited?
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.
What is the ticker symbol for LumiraDx Limited?
The ticker symbol for LumiraDx Limited is NASDAQ:LMDX
Does LumiraDx Limited pay dividends?
No, LumiraDx Limited does not pay dividends
What sector is LumiraDx Limited in?
LumiraDx Limited is in the Healthcare sector
What industry is LumiraDx Limited in?
LumiraDx Limited is in the Diagnostics & Research industry
What country is LumiraDx Limited based in?
LumiraDx Limited is headquartered in United Kingdom
When did LumiraDx Limited go public?
LumiraDx Limited's initial public offering (IPO) was on 19 March 2021
Is LumiraDx Limited in the S&P 500?
No, LumiraDx Limited is not included in the S&P 500 index
Is LumiraDx Limited in the NASDAQ 100?
No, LumiraDx Limited is not included in the NASDAQ 100 index
Is LumiraDx Limited in the Dow Jones?
No, LumiraDx Limited is not included in the Dow Jones index
When was LumiraDx Limited's last earnings report?
LumiraDx Limited's most recent earnings report was on 11 January 2024
When does LumiraDx Limited report earnings?
The date for LumiraDx Limited's next earnings report has not been announced yet
Should I buy LumiraDx Limited stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions